- Previous Close
46.48 - Open
47.12 - Bid 45.44 x --
- Ask 47.76 x --
- Day's Range
46.28 - 47.96 - 52 Week Range
20.74 - 55.75 - Volume
256 - Avg. Volume
4,244 - Market Cap (intraday)
3.066B - Beta (5Y Monthly) 1.05
- PE Ratio (TTM)
-- - EPS (TTM)
-16.03 - Earnings Date Jul 18, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Hansa Biopharma AB (publ), a biopharmaceutical company, engages in development and commercialization of treatments with rare immunological conditions using its proprietary enzyme technology platform. The company's lead drug candidate is Idefirix(imlifidase), which targets and cleaves all classes of immunoglobulin G (IgG) antibodies. It is also developing Novel immunoglobulin cleaving enzymes for Repeat dosing (NiceR) for the treatment of autoimmune diseases, transplantation, and oncology; and Enzyme based antibody Enhancement (EnzE), which is cancer immunotherapy. The company has a preclinical research collaboration agreement with argenx BV to evaluate the potential of combining imlifidase and efgartigimod to potentially be used in the acute and chronic setting of autoimmune diseases and transplantation. It also has a collaboration with Genethon to develop imlifidase as pre-treatment to gene therapy in Crigler-Najjar syndrome patients with anti-AAV antibodies. Hansa Biopharma AB (publ) was incorporated in 2007 and is headquartered in Lund, Sweden.
www.hansabiopharma.comRecent News: 0RC7.IL
View MorePerformance Overview: 0RC7.IL
Trailing total returns as of 6/28/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 0RC7.IL
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 0RC7.IL
View MoreValuation Measures
Market Cap
3.03B
Enterprise Value
3.43B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
14.78
Price/Book (mrq)
--
Enterprise Value/Revenue
20.69
Enterprise Value/EBITDA
-2.49
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-39.82%
Return on Equity (ttm)
-228.62%
Revenue (ttm)
158.7M
Net Income Avi to Common (ttm)
-759.23M
Diluted EPS (ttm)
-16.03
Balance Sheet and Cash Flow
Total Cash (mrq)
1.1B
Total Debt/Equity (mrq)
475.26%
Levered Free Cash Flow (ttm)
-368.35M